A minimally invasive outpatient procedure may offer an answer to one of weight-loss medicine's biggest problems: the rapid weight regain that happens when people stop taking Ozempic, Wegovy, or similar GLP-1 drugs. About 70% of patients who discontinue these medications pile the pounds back on within 18 months, often losing all metabolic benefits in the process.
Researchers presenting findings at Digestive Disease Week 2026 report the first blinded, randomized, sham-controlled evidence that a procedure called duodenal mucosal resurfacing can help people maintain weight loss long after stopping medication. The treatment uses controlled heat to remove damaged tissue from the inner lining of the duodenum, the first section of the small intestine below the stomach, encouraging growth of healthier tissue in its place.
The appeal is obvious. Nearly one in five U.S. adults with obesity has used GLP-1 therapy. Many quit because of cost, side effects, or simply preferring not to take a drug indefinitely. For those patients, the prospect of a one-time procedure that prevents rebound weight gain addresses what researchers call a massive unmet need.
Early trial data shows promise. Among 45 people who had lost at least 15% of body weight using tirzepatide before stopping it, 29 received the actual resurfacing treatment while 16 underwent sham surgery. Six months after stopping the drug, the gap was striking. Those who received the sham procedure regained roughly 40% more weight than those treated with the real procedure. The most extensively treated patients regained only about 7 pounds and kept more than 80% of their original weight loss, compared to the control group's much steeper rebound.
Perhaps most intriguing, the benefit appeared to strengthen rather than fade over the six-month observation window. That pattern suggests the procedure may be triggering lasting biological changes rather than producing temporary effects.
"What's particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response," said lead researcher Shelby Sullivan, MD, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center. "That gives us confidence that we're targeting the right biology."
The procedure works on a specific problem. Over time, diets high in fat and sugar can degrade the duodenum's lining, altering how the body processes food and manages the hormones GLP-1 drugs target. This degradation contributes to insulin resistance and metabolic dysfunction. By restoring a healthier mucosal layer, the procedure essentially resets the gut's metabolic signaling, allowing the body to maintain a lower set point even without medication.
Recovery is straightforward. Most patients return to normal activities within a day. No serious complications emerged in either the treatment or sham groups, and participants couldn't tell which procedure they received because symptoms are minimal.
The larger REMAIN-1 study, which includes more than 300 fully enrolled participants, is expected to deliver six-month results from the main cohort in the fourth quarter of 2026, with a potential marketing submission to follow. Duodenal mucosal resurfacing remains investigational for now, but these early findings suggest it could become a genuine option for the millions facing the weight-loss plateau that comes with stopping GLP-1 therapy.
Author Jessica Williams: "This is exactly the kind of unglamorous but practical innovation that could reshape obesity treatment for people who can't or won't stay on expensive drugs forever."
Comments